To include your compound in the COVID-19 Resource Center, submit it here.

Avastin bevacizumab: Phase III data

Data from the 2-year, U.S. Phase III CATT trial in 1,185 patients with neovascular AMD showed that intravitreal Avastin was non-inferior to Lucentis ranibizumab on the primary endpoint of mean change from baseline in visual acuity at 1 year when the drugs were administered on either a monthly schedule or on an as needed basis. Specifically, patients

Read the full 572 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers